Pharmacological and non-pharmacological interventions for adults with ADHD: protocol for a systematic review and network meta-analysis

Samuele Cortese 1,2,3,4,5, Cinzia Del Giovane 6,7, Samuel Chamberlain 8,9, Alexandra Philipsen 10, Susan Young 11, Andrea Bilbow 12,13, Andrea Cipriani 14,15

INTRODUCTION

It is unclear how pharmacological and non-pharmacological interventions compare with each other in terms of efficacy and tolerability for core symptoms and additional problems in adults with attention-deficit/hyperactivity disorder (ADHD). We aim to conduct the first network meta-analysis (NMA) comparing pharmacological and non-pharmacological interventions (or their combinations) in adults with ADHD.

Methods and analysis

We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for NMAs. We will search a broad set of electronic databases/registries and contact drug companies and experts in the field to retrieve published and unpublished randomised controlled trials (RCTs) (parallel or cross-over) of medications (either licensed or unlicensed) and any non-pharmacological intervention in adults (≥18 years) with ADHD. Primary outcomes will be: (1) change in severity of ADHD core symptoms, and (2) acceptability (all-cause discontinuation). Secondary outcomes will include tolerability (drop-out due to side effects) and change in the severity of emotional dysregulation, executive dysfunctions and quality of life. The risk of bias in each individual RCT included in the NMA will be assessed using the Cochrane Risk of Bias tool version 2. We will evaluate the transitivity assumption comparing the distribution of possible effect modifiers across treatment comparisons. We will perform Bayesian NMA for each outcome with random-effects model in OpenBUGS. Pooled estimates of NMA will be obtained using the Markov Chains Monte Carlo method. We will judge the credibility in the evidence derived from the NMA using the CIneMA tool (which includes assessment of publication bias). We will conduct a series of sensitivity analyses to assess the robustness of the findings.

Ethics and dissemination

As this is the protocol for an aggregate-data level NMA, ethical approval will not be required. Results will be disseminated at national/international conferences and in peer-reviewed journals.

PROSPERO registration number CRD42021265576.

Its impairing symptoms persist into adulthood in up to ~75% of childhood cases.3,4 Adult ADHD has a prevalence estimated at ~2.5%3 and is commonly comorbid with other disorders (eg, depression or anxiety)6 and with problems such as emotional dysregulation, which are often the main trigger for a referral to clinical services.5 If untreated, adult ADHD is associated with substantial societal burden, including significantly increased risk of unemployment, substance abuse, criminal acts, accidents and mortality.6 The personal and societal costs of untreated ADHD in adults are estimated at around £20 000/person/year.7

Both pharmacological and non-pharmacological (eg, psychological) treatments are available for adults with ADHD.8 Pharmacological and non-pharmacological interventions should be considered to be complementary, rather than mutually exclusive options. For instance, while stimulants...
are considered highly effective in decreasing the severity of adult ADHD core symptoms over the short-medium term (effect size, ES: ~0.8), their efficacy in the treatment of emotional dysregulation is lower (ES: ~0.3–0.5), suggesting the need for additional pharmacological or non-pharmacological options.

The current ADHD guidelines from the National Institute for Health and Care Excellence (NICE) recommend pharmacotherapy (stimulants followed by the selective norepinephrine reuptake inhibitor atomoxetine) as first-line treatment options for adult ADHD, with psychological therapies as second option. However, the recommendation on the sequencing of pharmacological and non-pharmacological options was based on one randomised clinical trial (RCT) only, comparing head-to-head pharmacotherapy and psychological treatment, retrieved from a literature search (up to 28 April 2017) that is now outdated. Since the NICE guidelines were published, a number of RCTs have been published pointing to significant efficacy and good tolerability of a variety of non-pharmacological interventions—including cognitive behavioural therapy, dialectic behavioural therapy, mindfulness, cognitive training and neurofeedback—for ADHD core symptoms and/or associated dysfunctions. Additionally, due to the paucity of RCTs, the NICE committee was not able to make any evidence-based recommendation on which type(s) of non-pharmacological treatments are preferred. This is highly problematic in particular for those patients who do not opt for or are unable to tolerate a pharmacologic treatment and need to be informed on the comparative efficacy/tolerability of currently available non-pharmacologic options. Furthermore, recent studies have assessed internet delivered non-pharmacological interventions, to possibly maximise efficiency and cost-effectiveness (eg, 14–16). This is particularly relevant considering the need for remote assessment/treatment prompted by the current pandemic-related restrictions and the likely push towards digital interventions in the post-COVID-19 era.

Therefore, there is a need for updated evidence synthesis regarding how non-pharmacological interventions—and different ways to deliver them—compare with each other, to pharmacologic treatments or to combinations of pharmacological and non-pharmacological interventions in terms of efficacy and tolerability on specific relevant outcomes (eg, ADHD core symptoms, emotional dysregulation and executive functions) in adults with ADHD.

A well-powered RCT would be suited to compare pharmacological and non-pharmacological options, but there are obvious financial and logistic constraints in conducting well-powered RCTs comparing all interventions for ADHD in adults. Network meta-analysis (NMA), which allows for the comparison of two or more interventions even when they have not been compared head-to-head in the studies included in the meta-analysis, provides a cost-effective, practical option to address this gap.

A scoping search in PubMed/Medline (PubMed Central and Europe PubMed Central), PsycINFO and Embase (up to 1 October 2021) using search terms for ‘ADHD’, ‘adults’ and ‘network meta-analysis’ did not find any NMA including, in the same network, pharmacologic and non-pharmacologic interventions for adults with ADHD. Based on our searches, no protocol for such NMA has been registered in PROSPERO or other registries at the time of writing.

Therefore, we aim to conduct the first systematic review/NMA of published and unpublished RCTs to assess the comparative efficacy and tolerability of UK licensed and unlicensed medications for ADHD, non-pharmacological treatments, or their combination, on ADHD core symptoms severity and related dysfunctions (eg, emotional dysregulation) in adults with ADHD.

METHODS AND ANALYSIS

The methods of the proposed study are based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and its extension for NMA. The methods are in line with those of another NMA of pharmacological and non-pharmacological interventions for depressive disorder.

The protocol of the present NMA is preregistered in PROSPERO.

We plan to start the study on 1 March 2022 and to complete it by 1 March 2024.

Search

We will update the search for RCTs of medications for ADHD from an NMA published in 2018 and conduct a de novo search for the non-pharmacological interventions. The search will be conducted with the support of Systematic Review Solutions Ltd. (SRS), an independent health research service company specialising in evidence-based medicine methods and meta-research training, production of systematic reviews and Health Technology Assessment reports, and development of clinical practice guidelines. SRS conducted the search for the previous NMA. Using a similar search strategy, we will search a broad set of electronic databases, including PubMed, BIOSIS Previews, CINAHL, the Cochrane Central Register of Controlled Trials, Embase, ERIC, MEDLINE, PsycINFO, OpenGrey, Web of Science Core Collection, ProQuest Dissertations and Theses (UK and Ireland), ProQuest Dissertations and Theses and the WHO International Trials Registry Platform, including ClinicalTrials.gov, with no language/type of document restrictions. For the specific syntax for each database, see online supplemental 1.

We will also search the US Food and Drug Administration, European Medicines Agency and relevant drug manufacturers’ websites for RCTs of medications. We will also endeavour to gather relevant unpublished data for pharmacological and non-pharmacological interventions by contacting drug companies, study authors and the
members of key scientific organisations of ADHD world-
wide. Specifically, we will contact the European Network
of Hyperkinetic disorder (Eunethydis), the World ADHD
Federation, the he American Professional Society of
ADHD and Related Disorders (APSGARD) and the Can-
dian ADHD Resource Alliance (CADDRA) to advertise
the study and query about the existence of any eligible
unpublished study.

Selection criteria
Study design
We will include parallel or cross-over RCTs of at least
1-week duration for pharmacological treatment, in line
with prior work, and of at least four sessions for psycho-
therapy. For cross-over studies of medications, to address
concerns around possible ‘carry over’ effects, we will use
data from the precross-over phase, when reported in
the paper. When data for the precross-over phase are not
reported, we will contact study authors to gather them. If
precross-over data are not reported and not available on
request, we will use data at the end point (after crossing
over), only if there was a washout period (as reported in
request, we will use data at the end point (after crossing
over) of the RCT

Outcomes
Primary outcomes: (1) change in severity of ADHD core
symptoms, according to a standardised rating scale. We
will consider separately self-rated ADHD core symptoms
and observer as well as clinician-rated symptoms; (2)
acceptability (all-cause discontinuation measured by the
proportion of patients who withdrew from the study for
any reason). Secondary outcomes: tolerability (drop-out
due to side effects); change in the severity of emotional
dysregulation, measured with any of the scales listed in
Lenzi et al, executive dysfunctions, based on any of the
scales in Tamminga et al, and quality of life, measured
with any of the scales listed in Tsujii et al.

Data collection
We will select studies, and extract/collect data in a two-step
process. First, two independent investigators will screen
the titles and abstracts we identified. Second, two inde-
pendent investigators will obtain and read the full texts of
all potentially relevant studies and determine the final list
of studies to include. Any disagreement will be resolved
by senior investigators. We will extract data into prespec-
tified data extraction forms. For each study, we will
extract information on study characteristics (eg, setting,
study design and sample size), participant characteris-
tics (eg, mean age and range, presence of comorbidities
and concomitant therapies), interventions and controls
eg, dose, frequency of treatment) and outcomes. We
will systematically contact study when needed to gather
unpublished information/data.

Study risk of bias assessment
The risk of bias in each individual RCT included in our
NMA will be assessed using the Cochrane Risk of Bias tool-
version 2 (RoB-2), as recommended in The Cochrane
Handbook of Systematic Reviews of Interventions. The
tool includes five domains through which bias might be
introduced into the result. For individually randomised
trials (including cross-over trials), these include:
1. Bias arising from the randomisation process.
2. Bias due to deviations from intended interventions.
3. Bias due to missing outcome data.
4. Bias in measurement of the outcome.
5. Bias in selection of the reported result.
We will use the appropriate templates for randomised parallel-group and cross-over trials, respectively.

Measures of treatment effects
For continuous outcomes, we will use mean difference (MD) as a measurement of treatment effect, with the relative 95% CI, when studies assessed the outcome with the same instruments; standardised mean difference (SMD, Cohen’s d) when studies used different instruments. We will use published mean values and standard deviations (SDs). If SDs are not available, they will be estimated by conversion from SEs, p-values, CIs or t-values. If none of the above values is available from the published paper, we will contact the authors of the study to obtain information. If the information is not provided by the study author, we will employ a validated method for imputation to derive missing SDs.

For dichotomous outcomes, we will calculate the OR and relative 95% CI. Missing dichotomous outcome data will be handled according to the intention-to-treat principle. Participants who drop out after randomisation will be considered as having a negative outcome.

Assessment of clinical and methodological heterogeneity within treatment comparisons
In each pairwise comparison, patient characteristics, treatments and outcome definitions of included studies should be similar. We will produce descriptive statistics for studies and study population characteristics across included trials to assess clinical and methodological heterogeneity. Within each pairwise comparison, we will compare these characteristics to assess the presence of clinical heterogeneity.

Assessment of transitivity across treatment comparisons
It is appropriate to use NMA if the assumption of transitivity can be defended. Transitivity holds when the distributions of the potential effect modifiers, like study and patient-level covariates, are balanced across all pairwise comparisons. To assess the transitivity assumption, we will compare the distribution of clinical and methodological variables (eg, ADHD severity at baseline, comorbidities, adherence and treatment duration) that could act as effect modifiers across treatment comparisons.

Data analysis
First, we will conduct conventional pairwise meta-analyses with a random-effects model in STATA V.16.1 for all outcomes and comparisons with at least two studies. Then, we will perform Bayesian NMA for each outcome with random-effects model in OpenBUGS, accounting for correlations induced by multiarm studies. Pooled estimates of NMA will be obtained using the Markov Chains Monte Carlo method. We will employ the binomial (dichotomous outcomes) and normal (continuous outcomes) likelihood functions and will use vague prior distributions for the treatment effects and a minimally informative prior distribution for the common heterogeneity SD depending on the outcome. We will examine Gelman-Rubin trace plots to check that multiple chains achieve convergence. All results will be reported as treatment effects (MD, SMD or OR) and their 95% credible intervals. NMA results will be presented in league tables and forest plots.

We will estimate heterogeneity variances for each pairwise comparison in standard pairwise meta-analyses and assess the presence of statistical heterogeneity by visually inspecting the forest plots and calculating the I-squared statistic. In the NMA, we will assume a common estimate for heterogeneity variance across comparisons and base our assessment of statistical heterogeneity in the whole network by comparing the magnitude of the common heterogeneity variance (τ2) with the empirical distribution as derived by Rhodes and Turner. We will also calculate the total I-squared statistic.

Statistical disagreement between direct and indirect effect sizes (incoherence) will be evaluated globally, by comparison of the fit and parsimony of consistency and inconsistency models, and locally, by calculation of the difference between direct and indirect estimates in all closed loops in the network. The node splitting method, which separates evidence on a particular comparison into direct and indirect evidence, will be used to calculate the inconsistency of the model. To determine whether the results are affected by possible effect modifiers, we will conduct network meta-regression and subgroup analysis according to the following variables: study sponsorship, treatment duration, comorbid psychiatric disorders, study risk of bias, mean baseline severity and percentage of participants treated with stable doses of medications in non-pharmacological RCTs.

We will finally conduct sensitivity analyses for primary outcomes by excluding trials without unpublished data, trials with imputed data, trials with overall sample size smaller than 20 and trials with non-blinded assessments. We will also conduct a sensitivity analysis combing guanfacine and clonidine in the same node.
Patient and public involvement

Our patient and public involvement coauthor, Ms. Bilbow, CEO of The National Attention Deficit Disorder Information and Support Service (ADDISS), one of the largest UK charities of patients with ADHD, has played a central role in the development of this protocol since its initial design. During the preparation of the present proposal, Ms. Bilbow liaised with representatives (patients) of ADDISS, and ADHD Europe to gather their feedback on the proposal; based on the feedback form patients, critically commented on the overarching plan of the application, highlighting that it covers an important gap perceived as crucial by patients with ADHD and their families; noted the importance of comparing different types of non-pharmacological interventions given the patchy provision across the UK and uncertainties around the evidence base supporting at least some types of non-pharmacological approaches; recommended inclusion of quality of life as a secondary outcome measure.

As this is a protocol, no patients were directly involved in this study.

ETHICS AND DISSEMINATION

Ethics

As this is the protocol of an aggregate-data level NMA, no ethical approval will be needed.

Dissemination

On publication, the full data set of the NMA and the codes for the analyses will be available online freely in Mendeley Data, a secure online repository for research data. The results of the study will be disseminated nationally, via conferences organised by groups of people with lived experience (e.g., National Attention Deficit Disorder Information and Support Service and ADHD Foundation) and professional organisations (e.g., UKAAP, Royal College of Psychiatrists). Results will also be disseminated internationally via conferences (for service users: e.g., annual meeting of ADHD Europe; for professionals, e.g., meetings of the WFA, Eunethydis, APSARD) and publications in peer-reviewed journals in the field of psychiatry/psychology and general medicine.

Author affiliations

1School of Psychology, Centre for Innovation in Mental Health (CIMH), Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK
2Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK
3Solent NHS Trust, Southampton, UK
4Hassfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York City, New York, USA
5Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK
6Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio, Modena, Italy
7Institute of Primary Health Care, University of Bern, Bern, Switzerland
8Department of Psychiatry, Faculty of Medicine, University of Southampton, Southampton, UK
9Southern Health NHS Foundation Trust, Southampton, UK
10Department of Psychiatry and Psychotherapy, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Germany
11Department of Psychology, Reykjavik University, Reykjavik, Iceland
12Attention Deficit Disorder Information and Support Service, London, UK
13ADHD-Europe, Brussels, Belgium
14Department of Psychiatry, University of Oxford, Oxford, UK
15Oxford Health NHS Foundation Trust, Oxford, UK

Contributors

SCo and AC designed the study. SCh contributed to the design, in particular in relation to the pharmacological interventions. AP and SY contributed to the design, in particular in relation to the non-pharmacological interventions. CDG contributed to the design, in particular in relation to the statistical analyses. AB contributed to the design, in particular in relation to PPI input. SCo drafted the first version of the manuscript. SCh, AP, SY, CDG, AB and AC critically revised the first version. Conduct, acquisition of data, analysis and interpretation of data are not applicable here as this is a protocol of a meta-analysis.

Funding

This project is funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RPB) Programme (Grant Reference Number NIHR203003), (Pr: SCo). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. SCh’s role in this study was funded by a Wellcome Trust Clinical Fellowship (110049/2/15/Z & 110049/2/15/A /). AC is supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR Research Professorship (grant RP-2017-08-ST2-006), by the NIHR Oxford and Thames Valley Applied Research Collaboration and by the NIHR Oxford Health Biomedical Research Centre (grant BRC-1215-20005).

Competing interests

SCo declares honoraria and reimbursement for travel and accommodation expenses for lectures from the following non-profit associations: Association for Child and Adolescent Central Health (ACAMH), Canadian ADHD Alliance Resource (CADDRA), British Association of Pharmacology (BAP) and from Healthcare Convention for educational activity on ADHD. SCh receives honoraria from Elsevier for editorial work. He previously consulted for Promentis. SCh receives honoraria from Elsevier for editorial work. He previously consulted for Promentis. AC has received research and consultancy fees from INQIPIT (Italian Network for Paediatric Trials), CARIPLO Foundation and Angelini Pharma, outside the submitted work.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Samuele Cortese http://orcid.org/0000-0001-5877-8075
Andrea Cipriani http://orcid.org/0000-0001-5179-8321

REFERENCES


